Tuesday June 2, 2020

Elan completes $3.25bn Tysabri sale

Irish-based drugmaker Elan Corporation has said that it has closed the sale of its share of multiple sclerosis drug Tysabri to its joint venture partner Biogen Idec.

3rd April, 2013
Elan chief executive Kelly Martin.

Irish-based drugmaker Elan Corporation has said that it has closed the sale of its share of multiple sclerosis drug Tysabri to its joint venture partner Biogen Idec.

Under the terms of the agreement, first announced in February, Elan has received $3.25 billion in cash and will receive double digit tiered royalty payments, on all indications, for the

life of Tysabri.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 5 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago